Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
about
Immunomodulatory agents in myelofibrosis.JAK2 V617F constitutive activation requires JH2 residue F595: a pseudokinase domain target for specific inhibitorsA Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition.Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
P2860
Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@en
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@nl
type
label
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@en
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@nl
prefLabel
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@en
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@nl
P2860
P1476
Emerging drugs for the therapy ...... lycythemia vera myelofibrosis.
@en
P2093
Ruben A Mesa
P2860
P304
P356
10.1517/14728210903066809
P407
P577
2009-09-01T00:00:00Z